相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Statin-Ezetimibe Combination Therapy In Diabetic Individuals
Theodosios D. Filippatos et al.
ANGIOLOGY (2016)
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)
Shona J. Livingstone et al.
DIABETOLOGIA (2016)
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
Ioanna Gouni-Berthold et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
Helen M. Colhoun et al.
EUROPEAN HEART JOURNAL (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia
Anastazia A. Kei et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Hyaluronidase hypersensitivity: A rare complication of peribulbar block
A. R. Rajalakshmi et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2016)
Effects of ezetimibe/simvastatin combination on metabolic parameters
Theodosios D. Filippatos et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease
Tsuyoshi Nozue et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
Statin therapy with or without ezetimibe and the progression to diabetes
Fotios Barkas et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd-Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
Peter P. Toth et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
Tsuyoshi Nozue et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy
Wijtske Annema et al.
TRANSLATIONAL RESEARCH (2016)
Pitavastatin and carbohydrate metabolism: what is the evidence?
T. D. Filippatos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
CETP Inhibition: Past Failures and Future Hopes
Constantine E. Kosmas et al.
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY (2016)
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
T. D. Filippatos et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2016)
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy
Carlos Aguiar et al.
ATHEROSCLEROSIS SUPPLEMENTS (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Safety considerations with fenofibrate/simvastatin combination
Theodosios D. Filippatos et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Current lipid-modifying agents
Aris P. Agouridis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials
Chi-kin Ip et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
G. Kees Hovingh et al.
LANCET (2015)
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
John J. P. Kastelein et al.
LANCET (2015)
A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia
Itori Saito et al.
LIPIDS IN HEALTH AND DISEASE (2015)
Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition
Eugene Chang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease
Y. Zhang et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
PCSK9 Inhibition: Does Lipoprotein Size Matter?
Karim Si-Tayeb et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose
Christos V. Rizos et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome
Kyoko Ohbu-Murayama et al.
Journal of Diabetes Investigation (2015)
Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
Michael J. Koren et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Lipids and lipid management in diabetes
Mamta Jaiswal et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
Sebhat Erqou et al.
DIABETOLOGIA (2014)
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial
Yumie Takeshita et al.
DIABETOLOGIA (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A novel 3D 2-photon imaging of unsectioned transparent mouse brain to assess neuronal injury, vascular disruption, microglial activation and tissue-axon degeneration and regeneration using morphology preserving optical clearing agent for circuit reconstruction at an unprecedented depth
Manoj K. Jaiswal et al.
BRAIN INJURY (2014)
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia
Elisavet Moutzouri et al.
ATHEROSCLEROSIS (2013)
Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles
Marcus Stahlman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Effects of High-Density Lipoprotein Elevation With Cholesteryl Ester Transfer Protein Inhibition on Insulin Secretion
Andrew L. Siebel et al.
CIRCULATION RESEARCH (2013)
Fenofibrate and the kidney: an overview
Michael S. Kostapanos et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels
Elisavet Moutzouri et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2013)
Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes
Theodosios D. Filippatos et al.
LIPIDS (2013)
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Rose Q. Do et al.
CURRENT CARDIOLOGY REPORTS (2013)
High density lipoprotein and cardiovascular diseases
Theodosios D. Filippatos et al.
WORLD JOURNAL OF CARDIOLOGY (2013)
Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia
Jinrui Guo et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Emphasizing Statin Safety in the Hospitalized Patient: A Review
Alicia Leung et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program
Evan A. Stein et al.
ATHEROSCLEROSIS (2012)
Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - Induced cytokine production in monocytes of hypercholesterolemic patients
Elisavet Moutzouri et al.
ATHEROSCLEROSIS (2012)
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
Doralisa Morrone et al.
ATHEROSCLEROSIS (2012)
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
Theodosios D. Filippatos
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Uchechukwu K. Sampson et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Simvastatin interactions with other drugs
Matilda Florentin et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome
A. P. Agouridis et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Use of Administrative Data to Estimate the Incidence of Statin-Related Rhabdomyolysis
James S. Floyd et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia
Michael S. Kostapanos et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2012)
The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin
Jonathan R. Murrow et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2012)
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Ronald M. Krauss et al.
JOURNAL OF LIPID RESEARCH (2012)
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Paul M. Ridker et al.
LANCET (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes
Shinji Ichimori et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Clinical aspects of PCSK9
Bertrand Cariou et al.
ATHEROSCLEROSIS (2011)
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
Meng Lee et al.
ATHEROSCLEROSIS (2011)
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip J. Barter et al.
CIRCULATION (2011)
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes
Manfredi Rizzo et al.
CLINICAL LIPIDOLOGY (2011)
Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study
Michel Farnier et al.
CLINICAL THERAPEUTICS (2011)
Role of Phospholipid Transfer Protein in High-Density Lipoprotein- Mediated Reverse Cholesterol Transport
Amirfarbod Yazdanyar et al.
CURRENT ATHEROSCLEROSIS REPORTS (2011)
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia
Matilda Florentin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Dimitri P. Mikhailidis et al.
Current Vascular Pharmacology (2011)
Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
L. A. Leiter et al.
DIABETIC MEDICINE (2011)
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
Aris P. Agouridis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Theodosios D. Filippatos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient
Gerald F. Watts et al.
HEART (2011)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n-3 Fatty Acids in Mixed Dyslipidemia
A. P. Agouridis et al.
LIPIDS (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials
E. J. Mills et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2011)
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
Aris P. Agouridis et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2011)
Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
Stephen J. Nicholls et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials
Peter H. Jones et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia A Randomized, Double-Blind Study
Eli M. Roth et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
Manfredi Rizzo et al.
ANGIOLOGY (2010)
Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia
Vasilis Tsimihodimos et al.
ATHEROSCLEROSIS (2010)
Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia - A Phase 3 Study
Eli M. Roth et al.
CARDIOVASCULAR DRUGS AND THERAPY (2010)
Combination of Fenofibrate with Non-Statin Drug Regimens
A. P. Agouridis et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Matilda Florentin et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Do Statins Beneficially or Adversely Affect Glucose Homeostasis?
Michael S. Kostapanos et al.
Current Vascular Pharmacology (2010)
Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes - The FIELD Helsinki substudy
Carol Forsblom et al.
DIABETES CARE (2010)
Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
Robert Krysiak et al.
DIABETES CARE (2010)
Pleiotropic effects of ezetimibe: Do they really exist?
Michalis Kalogirou et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?
M. Rizzo et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Pleiotropic Effects of Atorvastatin on Monocytes in Atherosclerotic Patients
Zhi-hao Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
LANCET (2010)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun et al.
LANCET (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
E. S. Nakou et al.
LIPIDS (2010)
Combination Lipid Therapy in Type 2 Diabetes
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
Emily Y. Chew et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study
Syed M. Mohiuddin et al.
AMERICAN HEART JOURNAL (2009)
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study
Peter H. Jones et al.
ATHEROSCLEROSIS (2009)
The Relationship Between Reduction in Low-Density Lipoprotein Cholesterol by Statins and Reduction in Risk of Cardiovascular Outcomes: An Updated Meta-Analysis
Philippa J. Delahoy et al.
CLINICAL THERAPEUTICS (2009)
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
Giuseppe Derosa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Pleiotropic Effects of Statins - Clinical Evidence
Vasilios G. Athyros et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
T. D. Filippatos et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Effects of Atorvastatin 10 mg and Fenofibrate 200 mg on the Low-Density Lipoprotein Profile in Dyslipidemic Patients: A 12-Week, Multicenter, Randomized, Open-Label, Parallel-Group Study
Jean-Claude Ansquer et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2009)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles
K. Winkler et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2009)
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention
Pierre Amarenco et al.
LANCET NEUROLOGY (2009)
Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome
K. G. Lagos et al.
LIPIDS (2009)
Comparison of effects of Simvastatin alone versus Fenofibrate alone versus Simvastatin plus Fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the diabetes and combined lipid therapy regimen study)
Heidi T. May et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Statins and heart failure
Theodosios D. Filippatos et al.
ANGIOLOGY (2008)
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Kiranbir Josan et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2008)
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia
E. S. Nakou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Multiple actions of high-density lipoprotein
Matilda Florentin et al.
CURRENT OPINION IN CARDIOLOGY (2008)
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
T. D. Filippatos et al.
DIABETES OBESITY & METABOLISM (2008)
Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women
Irene F. Gazi et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2008)
Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia
Michael S. Kostapanos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Theodosios Filippatos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study
C. S. Derdemezis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study
M. Florentin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia
E. S. Nakou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
Kaspar Berneis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2008)
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Edward J. Mills et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Statins and diabetes - Reply
Patricia M. Kearney et al.
LANCET (2008)
Ezetimibe-associated adverse effects: what the clinician needs to know
M. Florentin et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Statin-associated adverse effects beyond muscle and liver toxicity
D. N. Kiortsis et al.
ATHEROSCLEROSIS (2007)
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
D. P. Mikhailidis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
T. D. Filippatos et al.
ATHEROSCLEROSIS (2007)
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia
Michael S. Kostapanos et al.
CLINICAL THERAPEUTICS (2007)
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia
Mihalis Kalogirou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes
M. Rizzo et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2007)
Risk factors for statin-associated rhabdomyolysis
Stephanie Schech et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes
Anna Tokuno et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia - The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study
Joseph B. Muhlestein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Robert H. Knopp et al.
DIABETES CARE (2006)
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria
Irene Gazi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol
Irene F. Gazi et al.
LIPIDS (2006)
Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation
L Persegol et al.
DIABETOLOGIA (2006)
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Joao Costa et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Clinical perspectives of statin-induced rhabdomyolysis
KA Antons et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Statin safety: An appraisal from the adverse event reporting system
MH Davidson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
LDL cholesterol estimation in patients with the metabolic syndrome
Irene Gazi et al.
LIPIDS IN HEALTH AND DISEASE (2006)
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention
Z Zhou et al.
AMERICAN HEART JOURNAL (2006)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R Huxley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Low-density lipoprotein size and cardiovascular risk assessment
M Rizzo et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2006)
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma
I Gazi et al.
CLINICAL CHEMISTRY (2005)
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
TD Filippatos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial)
SM Grundy et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Reporting rate of Rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
PN Durrington et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Comparison of fluvastatin plus fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trial
G Derosa et al.
CLINICAL THERAPEUTICS (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia
W Le Goff et al.
PHARMACOLOGY & THERAPEUTICS (2004)
Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia
C Stefanutti et al.
CLINICAL DRUG INVESTIGATION (2004)
Diabetic dyslipidaemia: from basic research to clinical practice
MR Taskinen
DIABETOLOGIA (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Statin-associated myopathy
PD Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
MH Davidson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis et al.
JOURNAL OF LIPID RESEARCH (2002)
Fenofibrate increases creatininemia by increasing metabolic production of creatinine
C Hottelart et al.
NEPHRON (2002)
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
VG Athyros et al.
DIABETES CARE (2002)
Fibrate-induced increase in serum urea and creatinine levels
V Tsimihodimos et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
TH Taher et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Effects of fibrates on serum metabolic parameters
M Elisaf
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
VG Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - The MIRACL study: A randomized controlled trial
GG Schwartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
Current perspectives on statins
DJ Maron et al.
CIRCULATION (2000)
分享论文
